Search Results
Nov 14, 2025, 10:00 ET Ziegler Advises Infinity Hospice Care on its Strategic Partnership with LifeCare Home Health
/PRNewswire/ -- Ziegler, a specialty investment bank, is pleased to announce its role as exclusive financial and strategic advisor to Infinity Hospice Care (IHC) on its strategic partnership with LifeCare Home Health (LCHH).
More news about: Ziegler
Nov 14, 2025, 03:36 ET Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
6(6):429– 440 Lipton RB, et al. J Neurol. 2023;270(12);5692–5710 Takeshima T et al. ePresentation at IHC 2025 Ashina M, et al. Cephalalgia. 2020;40(3):241-254 Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377
More news about: H. Lundbeck A/S
Nov 07, 2025, 09:05 ET Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
reliance on additional IHC staining and enabling consistent analysis of the tumor immune microenvironment in both research and clinical practice. Lunit also introduced new data showcasing the utility of Lunit SCOPE uIHC, the company's AI-powered quantitative IHC platform, in mapping
More news about: Lunit
Nov 06, 2025, 17:31 ET Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight
platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/ 2+), pMMR primary advanced or recurrent endometrial cancer. In May 2025, AstraZeneca presented the data of the
More news about: DelveInsight Business Research, LLP
Nov 06, 2025, 15:49 ET LifeCare Home Health Family Expands Hospice Footprint with Acquisition of Infinity Hospice Care
Home Health ("LCHH"), a leading provider of Medicare-certified Home Health, Private Duty, and Hospice services, announced that Infinity Hospice Care ("IHC"), a trusted, family-owned hospice provider serving communities across Nevada and Arizona, has officially joined LCHH.
More news about: LifeCare Home Health Family
Nov 05, 2025, 16:07 ET Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
PB-223 specific binding to human tumor tissues by immunohistochemistry (IHC): PB-223 binds selectively to human tumor tissues and not to human normal tissue. PB-223 strongly reacted with colorectal, pancreatic, lung, prostate,
More news about: Precision Biologics
Nov 05, 2025, 08:00 ET Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings
Saturday, Nov 8, 2025: 12:15 - 1:45 PM, 5:10 - 6:35 PM A poster presentation on immunohistochemistry (IHC) detection of mesothelin to support further development of CAR T cell therapy in cholangiocarcinoma.Location: Prince George
More news about: Verismo Therapeutics
Nov 05, 2025, 05:01 ET Companion Diagnostics Market Worth USD 15.6 Bn by 2030 Growing at 12.4% CAGR, says Mordor Intelligence
Polymerase Chain Reaction (PCR) Immunohistochemistry (IHC) Real-Time PCR (RT-PCR) In Situ Hybridization (ISH) Next-Generation
More news about: Mordor Intelligence Private Limited
Oct 30, 2025, 08:35 ET Biocare Medical and Hamamatsu Announce Strategic Collaboration to Deliver Integrated Spatial Biology Solutions
ONCORE Pro X™ automated staining instrument. This integrated solution delivers a seamless, end-to-end workflow from multiplex immunofluorescence and IHC staining to high-resolution digital imaging, empowering pharmaceutical and biotech companies, academic research institutions, and contract research organizations
More news about: Biocare Medical
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
tumors regardless of CLDN18.2 expression receive ATG-022 (0.3-3.0 mg/kg Q3W) to evaluate safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥IHC 1+, 1%) patients are treated at 1.8 or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
More news about: Antengene Corporation Limited
Oct 20, 2025, 02:50 ET 2025 ESMO主席論壇口頭報告|維迪西妥單抗一線治療尿路上皮癌RC48-C016研究實現重大突破
1+/2+/3+）。在接受HER2檢測的765例患者中，632例患者具有HER2表達的特徵（IHC 1+/2+/3+），約占接受HER2檢測患者人群的82.6%。該研究共納入484例患者，以1:1方式隨機分組。本研究設計中預設了分層因素，主要包括順鉑是否耐受、HER2表達狀態（HER2 IHC 1+ vs IHC 2+/3+）及是否有內臟轉移情況等。 結果顯示，維迪西妥單抗聯合特瑞普利單抗方案的療效獲益在所有預設亞組中均表現一致。無論患者HER2表達狀態及順鉑耐受性如何，無論腫瘤發生於上尿路還是下尿路，維迪西妥單抗聯合特瑞普利單抗相比化療均顯著改善PFS和OS，有力證明了其在尿路上皮癌全人群的獲益。
More news about: 榮昌生物製藥（煙台）股份有限公司
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
HER2-overexpressing (IHC 2+/3+) advanced or metastatic urothelial carcinoma, demonstrating excellent efficacy and consistent safety with that observed in prior clinical trials. RC48-C016 study prospectively extended its clinical design to the full HER2-expressing population (IHC 1+/2+/3+).
More news about: RemeGen Co., Ltd
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
to receive trastuzumab botidotin or T-DM1. 53% of patients had received ≥2 lines of anti-HER2 therapy, 61% of patients had HER2 Immunohistochemistry (IHC) 3+, and 60% of patients had been treated with TKIs, particularly pyrotinib (56%). As of April 26, 2025, median follow-up was 14.9 months.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
expression receive ATG-022 once every three weeks (0.3-3.0 mg/kg Q3W) to evaluate the safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥ IHC 1+, 1%) patients are treated at 1.8 mg/kg or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety. ATG-022 has
More news about: Antengene Corporation Limited
Oct 14, 2025, 08:30 ET Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
poster presentations. The studies highlight Caris' continued leadership in applying next-generation sequencing (WES and WTS), immunohistochemistry (IHC) and real-world clinico-genomic data to uncover actionable insights. Tumor types represented include colorectal, gastric, breast, pancreatic, head &
More news about: Caris Life Sciences
Oct 14, 2025, 00:00 ET Abu Dhabi's ADI Foundation Advances Mission to Bring One Billion People into the Digital Economy by 2030
About ADI FoundationADI Foundation is an Abu Dhabi-based organization founded by Sirius International Holding (a subsidiary of IHC), dedicated to empowering governments and institutions in emerging markets through blockchain infrastructure and partnerships needed to unlock sovereign
More news about: The ADI Foundation
Oct 14, 2025, 00:00 ET Abu Dhabi's ADI Foundation Advances Mission to Bring One Billion People into the Digital Economy by 2030
ADI Foundation is an Abu Dhabi-based organization founded by Sirius International Holding (a subsidiary of IHC), dedicated to empowering governments and institutions in emerging markets through blockchain infrastructure and partnerships needed to unlock sovereign
More news about: The ADI Foundation
Oct 07, 2025, 14:11 ET Circulogene Expands Solid Tumor Genomic Capabilities with Launch of OncoGenDx Tissue Assay
Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD)—to support both targeted therapy and immunotherapy decision-making. PD-L1 IHC (22C3 clone) is also available as an add-on service using CPS scoring. Ordering is streamlined through direct submission to Circulogene,
More news about: Circulogene
Sep 24, 2025, 09:00 ET Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
immunology. The company has participated in more than 1,000 clinical studies—including 75 Phase III PMA trials—developed over 250 unique IHC assays, and performs more than 100,000 IHC stainings annually. The collaboration aims to broaden access to the Lunit SCOPE® suite, Lunit's
More news about: Lunit
Sep 15, 2025, 10:45 ET Immunohistochemistry Market worth US$5.14 billion by 2030 with 7.6% CAGR | MarketsandMarkets™
the period. The increasing number of cancer cases is one of the key factors driving the uptake of IHC products, which, in turn, leads to a greater need for accurate and efficient diagnostic tools such as IHC tests. Additionally, market players have increasingly focused on innovation, including developing
More news about: MarketsandMarkets
Sep 11, 2025, 08:46 ET Korea University Study Reveals Hidden Complexity in Recurrent Brain Tumors
transcriptional changes as tumors transitioned to recurrence. Findings were further validated using external RNA-seq datasets and immunohistochemistry (IHC), strengthening the robustness of the results. The study uncovered several key insights. Recurrent meningiomas exhibited markedly higher proliferative
More news about: Korea University College of Medicine
Sep 11, 2025, 02:27 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
presentation at IHC 2025 2. Takeshima T et al. ePresentation at IHC 2025 3. Yu S et al. Oral presentation at IHC 2025 4. Lipton RB et al. Oral presentation at IHC 2025 5. Tepper SJ et al. ePresentation at IHC 2025 6. Yu S et al. ePresentation at IHC 2025 7.
More news about: H. Lundbeck A/S
Sep 11, 2025, 02:23 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
presentation at IHC 2025 2. Takeshima T et al. ePresentation at IHC 2025 3. Yu S et al. Oral presentation at IHC 2025 4. Lipton RB et al. Oral presentation at IHC 2025 5. Tepper SJ et al. ePresentation at IHC 2025 6. Yu S et al. ePresentation at IHC 2025 7.
More news about: H. Lundbeck A/S